Oxycodone SR is under clinical development by Avecho Biotechnology and currently in Phase II for Postherpetic Neuralgia. According to GlobalData, Phase II drugs for Postherpetic Neuralgia have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Oxycodone SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oxycodone SR overview
Oxycodone (sustained release) or TPM oxycodone (Targeted Penetration Matrix oxycodone) is under development for the treatment of postherpetic neuralgia and localized pain. It is formulated as a patch and administered through transdermal. The patch acts by providing sustained-release of oxycodone into the bloodstream. The drug candidate is based on TPM (Targeted Penetration Matrix) technology. It was under development for osteoarthritic pain.
Avecho Biotechnology overview
Avecho Biotechnology (Avecho), formerly known as Phosphagenics, is a research-driven biotechnology firm that develops and commercializes human and animal health products. The company’s drug delivery technology tocopheryl phosphate mixture (TPM) is derived from vitamin E using a proprietary and patented process that improves the solubility and oral, dermal, and transdermal adsorption of drugs and nutrients. Avecho’s product portfolio includes daptomycin, diclofenac gel, propofol injection, oxymorphone patch, oxycodone patch, tretinoin gel and transdermal opioid patches. The company also develops cannabinoid products in partnership with major drug manufacturers. It markets products under Vital ET and TPM brand names. It has business presence in Australia, India, Switzerland, and the US. Avecho is headquartered in Clayton, Victoria, Australia.
For a complete picture of Oxycodone SR’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
